Peptech patent approved
Tuesday, 15 July, 2003
Peptech's application for a patent on antibodies or antibody fragments that bind to a specific tumour necrosis factor (TNF) has been given the green light by US patent authorities.
Managing director Mr Stephen Kwik noted that the new patent enhanced the company's already considerable anti-TNF patent portfolio, and offered the potential for further coverage under the current description.
"As the peptide represents a portion of the TNF molecule, anti-TNF antibodies that bind the peptide could fall under the scope of the patent," Kwik said.
Peptech has already licensed its technology in the fields of antibody therapeutics for inflammatory diseases such as rheumatoid arthritis, psoriasis and Crohn's disease.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
